What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Diabetes mellitus
- Type 2 diabetes
Simon Heller mostly deals with Diabetes mellitus, Internal medicine, Hypoglycemia, Type 2 diabetes and Randomized controlled trial.
His Diabetes mellitus study combines topics in areas such as Surgery and Intensive care medicine.
His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology, Endocrinology and Cardiology.
His Hypoglycemia research is multidisciplinary, relying on both QT interval, Heart rate, Evidence-based medicine and Risk factor.
The various areas that Simon Heller examines in his Type 2 diabetes study include Weight loss, Nephropathy, Proportional hazards model, Vascular disease and Disease.
The concepts of his Randomized controlled trial study are interwoven with issues in Physical therapy, Quality of life, Cohort study and Clinical trial.
His most cited work include:
- Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. (5527 citations)
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes (1769 citations)
- Severe Hypoglycemia and Risks of Vascular Events and Death (1032 citations)
What are the main themes of his work throughout his whole career to date?
Simon Heller spends much of his time researching Diabetes mellitus, Internal medicine, Type 1 diabetes, Hypoglycemia and Type 2 diabetes.
The study incorporates disciplines such as Randomized controlled trial, Surgery and Intensive care medicine in addition to Diabetes mellitus.
His Internal medicine research incorporates elements of Endocrinology and Cardiology.
His work investigates the relationship between Type 1 diabetes and topics such as Physical therapy that intersect with problems in Quality of life and Cluster randomised controlled trial.
His study looks at the relationship between Hypoglycemia and fields such as QT interval, as well as how they intersect with chemical problems.
His work deals with themes such as Placebo, Proportional hazards model and Acute coronary syndrome, which intersect with Type 2 diabetes.
He most often published in these fields:
- Diabetes mellitus (45.95%)
- Internal medicine (42.38%)
- Type 1 diabetes (38.57%)
What were the highlights of his more recent work (between 2018-2021)?
- Type 1 diabetes (38.57%)
- Diabetes mellitus (45.95%)
- Internal medicine (42.38%)
In recent papers he was focusing on the following fields of study:
His main research concerns Type 1 diabetes, Diabetes mellitus, Internal medicine, Type 2 diabetes and Insulin.
His Type 1 diabetes study incorporates themes from Psychological intervention, Quality of life, Randomized controlled trial, Physical therapy and Glucose management.
Simon Heller mostly deals with Hypoglycemia in his studies of Diabetes mellitus.
His work carried out in the field of Internal medicine brings together such families of science as Placebo and Cardiology.
Simon Heller interconnects Clinical endpoint, Clinical trial, Post-hoc analysis, Disease and Myocardial infarction in the investigation of issues within Type 2 diabetes.
The Insulin study combines topics in areas such as Rate ratio, Incidence and Cohort.
Between 2018 and 2021, his most popular works were:
- Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (499 citations)
- International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors (96 citations)
- Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management (65 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Diabetes mellitus
- Type 2 diabetes
His scientific interests lie mostly in Type 1 diabetes, Diabetes mellitus, Internal medicine, Type 2 diabetes and Insulin.
His biological study spans a wide range of topics, including Psychological intervention, Randomized controlled trial, Intensive care medicine, Glucose management and Health professionals.
His work in the fields of Diabetes mellitus, such as Hypoglycemia and American diabetes association, overlaps with other areas such as Position statement.
His Hypoglycemia research is multidisciplinary, incorporating perspectives in Glycated hemoglobin, Diabetic ketoacidosis, Proinflammatory cytokine and Blood pressure.
Internal medicine is closely attributed to Endocrinology in his work.
His Type 2 diabetes study combines topics from a wide range of disciplines, such as Clinical endpoint and Clinical trial.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
